How are you handling phenytoin injection with the introduction of USP 800?

a. Will you allow stat bedside compounding for emergencies?
b. PPE requirements
c. CSTD?

Thanks!

At our facility, we only have the Tevadaptor/onguard closed system transfer device (CSTD). However, we are having difficulties using this CSTD to transfer chemo agents (eg. Mitomycin) to the toomey syringe for administration.

How are other organizations transferring to toomey syringes using a CSTD?

Can anyone share their process for storing/securing controlled medications, i.e. fentanyl or morphine drips, non-formulary controlled meds, delivered to the patient care areas when for some reason they cannot be administered right away, the patient is refusing, or patient has been discharged?

Good afternoon,

Does anyone has experience with restricting antipsychotics to be only available as scheduled or one time doses? CMS has been heavily advocating for that and we were cited by them for having PRN orders for Haldol. They are stating antisychotics should be only once or scheduled no PRN at all.

Thanks,
Mohamed

Does anyone have a policy or best practice around patients bringing in medications to be administered in the outpatient clinic setting (i.e., allergy shots from another provider, pen G from the pharmacy)?

Does anyone have a safe process to identify patient out-of-pocket costs for DOACs prior to discharge...without 'test prescriptions'?

Historically provider teams have sent 'test prescriptions' to retail pharmacies. As reported in previous ISMP newsletters, we also have experienced wrong drug and duplicate therapy errors with 'test prescription' miss-adventures. Therefore, our current stance is to not allow 'test prescriptions'.

Thank you in advance! Lu

Dear colleagues,

I would appreciate your response to the following questions:

Have you contacted B. Braun or Baxter in the past with an ask to print the NDC barcode in black-colored print to facilitate BCMA compliance?
If yes, what was the response?
If no, would you consider signing on to a petition letter (attached) to support our ask? Please reach out to daniel.kudryashov@med.usc.edu

Hi All

Our organization completed the ISMP IV push safety gap analysis survey. Our improvement opportunities were to:
1. clearly define who has privileges to perform IV push medication preparation and administration
2. define in policy the difference between IV push and a bolus medication

How does your organization define the privileges and IVP versus a bolus?

Thank you very much,
Andrea Gimpel-Blanchard, PharmD
Director of Pharmacy
MaineGeneral Medical Center
Augusta, ME 04330

Does anyone use this diluted form of epinephrine at their hospital for hypotensive patients? our ED physicians have been using this push dose over other pressors due to it's effects on both alpha and beta receptors. They are drawing up and diluting this on their own which is a huge concern for safety risks and dilution errors. Wondering if anyone has experience with this and how we can provide this med without causing confusion with 1 mg/ml concentrations or 1mg/10ml carpujects used in ACLS code blue situations.